Alcobra Ltd.
- Country
- 🇮🇱Israel
- Ownership
- Private, Subsidiary
- Established
- 2008-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
8
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Alcobra Ltd.
- Target Recruit Count
- 283
- Registration Number
- NCT02477748
- Locations
- 🇺🇸
Harmonex, Inc., Dothan, Alabama, United States
🇺🇸Pharmacology Research Institute, Newport Beach, California, United States
🇺🇸Artemis Institute for Clinical Research, San Diego, California, United States
Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects
- Conditions
- ADHD, Predominantly Inattentive Type
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-07-15
- Last Posted Date
- 2015-03-04
- Lead Sponsor
- Alcobra Ltd.
- Target Recruit Count
- 83
- Registration Number
- NCT02189772
- Locations
- 🇮🇱
Rambam Medical Center, Haifa, Israel
🇮🇱Shalvata Mental Health Center, Hod Hasharon, Israel
🇮🇱Hadassah-Hebrew University Medical Center,, Jerusalem, Israel
A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome
- Conditions
- Fragile X Syndrome
- Interventions
- Drug: MG01CI extended-release tablet
- First Posted Date
- 2014-04-30
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alcobra Ltd.
- Target Recruit Count
- 62
- Registration Number
- NCT02126995
- Locations
- 🇺🇸
Southwest Autism Research & Resource Center, Phoenix,, Arizona, United States
🇺🇸University of California Davis Pediatrics, Sacramento,, California, United States
🇺🇸Children's Hospital Colorado, Aurora,, Colorado, United States
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
- Conditions
- ADHDAttention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type
- Interventions
- Drug: placeboDrug: MG01CI (1400 mg)
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Alcobra Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT02059642
- Locations
- 🇺🇸
Sarkis Clinical Trials, Gainesville, Florida, United States
🇺🇸Miami Research, South Miami, Florida, United States
🇺🇸Capstone Clinical Research, Libertyville, Illinois, United States
A Phase 1 Study to Assess Pharmacokinetics of Metadoxine (MG01CI) 1400 mg, Administered to Healthy Volunteers
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Alcobra Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT01933997
- Locations
- 🇮🇱
Clinical research center Souraski medical center, Tel Aviv, Israel
- Prev
- 1
- 2
- Next